Veru has secured FDA feedback that clarifies a regulatory path for enobosarm as an adjunct to GLP-1 receptor agonists in obesity, with incremental weight loss over GLP-1 monotherapy as an approvable primary endpoint and preservation of physical function and body composition recognized as clinically meaningful secondary outcomes. The company will initiate a 200-patient Phase 2b Plateau trial in the first quarter of 2026 in adults aged 65 and older with a BMI of at least 35 who are initiating GLP-1 therapy, using enobosarm 3 mg, with a 72-week primary endpoint of percent change in total body weight. Interim data at 36 weeks will assess lean and fat mass by DEXA. Veru ended fiscal 2025 with $15.8 million in cash and added approximately $23.4 million after year-end to fund the program.
The signal here is a potential broadening of how obesity therapies are evaluated and reimbursed. If regulators and payers begin to reward not only total weight lost but also the quality of that weight loss—preferential fat reduction with preserved muscle and function—adjacent mechanisms like SARMs could find a foothold alongside incretins. The question is whether incremental weight loss plus functional gains can clear the evidentiary bar to justify combination use and pricing in a category dominated by powerful monotherapies.
This matters now because GLP-1 plateau and lean mass depletion are emerging as clinical and commercial friction points. In a prior 16-week study in older patients on semaglutide, enobosarm preserved lean mass, shifted tissue loss toward fat, and mitigated declines in stair-climb power; a higher-BMI subset also showed incremental weight loss and a greater proportion reaching at least 5% weight loss. While short and exploratory, those data frame the Plateau trial’s focus on a population at higher risk of functional compromise and with more weight to lose, and a design anchored to 12‑month maintenance outcomes, during which many patients stall. Framing the program around an FDA-endorsed ≥5% placebo-corrected weight loss at 52 weeks—or a fallback of meaningful functional preservation if weight loss is similar—aligns with real-world treatment dynamics and points to potential labeling pathways beyond pure appetite suppression.
For payers, an adjunct that extends weight loss and preserves function in older, high-BMI patients could translate to avoided falls, fractures, and disability, but evidence will need to quantify downstream cost offsets, not just DEXA curves. Medical Affairs teams should plan for pragmatic data on mobility, activities of daily living, and persistence after GLP-1 dose stabilization or discontinuation. HCPs will need infrastructure for body composition measurement and standardized functional tests, and coding and workflows may determine adoption as much as efficacy. Practical issues also loom: access to GLP-1 supply for trials, adherence in combination regimens, and monitoring for androgenic safety signals in diverse populations.
Competition is moving toward combination strategies that stack mechanisms for greater efficacy or durability—dual- or triple-incretin combinations, amylin analogs, and glucagon-based add-ons. Enobosarm differentiates by targeting muscle preservation rather than just incremental kilograms. If regulators ultimately sanction approval based on functional benefits with similar weight-loss outcomes, it could legitimize a new class of “quality-of-weight-loss” adjuncts and reshape brand strategies around body composition and performance, not just scale.
With modest cash and a long readout horizon, partnering with incretin leaders or specialty cardio-metabolic players seems likely. The next strategic fulcrum is whether guidelines and payer frameworks will institutionalize lean mass and function metrics alongside weight, or keep the market anchored to cost per kilogram lost.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
